Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21541951 | 1.00 | HPGD (0.67) | HPGDP2RX7KMT2ATSHRKDM4E | |
| SCHEMBL29418795 | 1.00 | HPGD (0.67) | HPGDP2RX7KMT2ATSHRKDM4E | |
| SCHEMBL29418612 | 1.00 | HPGD (0.67) | HPGDP2RX7KMT2ATSHRKDM4E | |
| SCHEMBL20477540 | 0.83 | HPGD (0.63) | HPGDPOLBSCN9A | |
| SCHEMBL29418710 | 0.83 | HPGD (0.63) | HPGDPOLBSCN9A | |
| SCHEMBL20477566 | 0.83 | HPGD (0.63) | HPGDPOLBSCN9A | |
| SCHEMBL29418763 | 0.83 | HPGD (0.63) | HPGDPOLBSCN9A | |
| Bimokalner SCHEMBL22017037 | 0.81 | HPGD (0.67) | HPGDKMT2AKDM4EMEN1POLB | |
| Bimokalner SCHEMBL20477551 | 0.81 | HPGD (0.67) | HPGDKMT2AKDM4EMEN1POLB | |
| Bimokalner SCHEMBL20477545 | 0.81 | HPGD (0.67) | HPGDKMT2AKDM4EMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247332-B1 | NON-AQUEOUS GEL COMPOSITION | ACOUSIA THERAPEUTICS GMBH (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4725937-A1 | PROCESS FOR THE SYNTHESIS OF BICYCLIC CARBOXAMIDE COMPOUNDS | Acousia Therapeutics GmbH (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-4362916-A1 | AQUEOUS GEL COMPOSITION | Acousia Therapeutics GmbH (DE) | 2024-05-08 | — | — | EP | claimed |
| US-20240009149-A1 | NON-AQUEOUS GEL COMPOSITION | ACOUSIA THERAPEUTICS GMBH (DE) | 2024-01-11 | — | — | US | claimed |
| WO-2023222795-A1 | AQUEOUS GEL COMPOSITION | ACOUSIA THERAPEUTICS GMBH (DE) | 2023-11-23 | — | — | WO | claimed |
| EP-4279061-A1 | AQUEOUS GEL COMPOSITION | Acousia Therapeutics GmbH (DE) | 2023-11-22 | — | — | EP | claimed |
| EP-4247332-A1 | NON-AQUEOUS GEL COMPOSITION | Acousia Therapeutics GmbH (DE) | 2023-09-27 | — | — | EP | claimed |
| WO-2022106523-A1 | NON-AQUEOUS GEL COMPOSITION | ACOUSIA THERAPEUTICS GMBH (DE) | 2022-05-27 | — | — | WO | claimed |
| EP-3484863-B1 | CYCLIC AMIDES AS POTASSIUM CHANNEL OPENERS | ACOUSIA THERAPEUTICS GMBH (DE) | 2020-06-17 | — | — | EP | claimed |
| US-20200157072-A1 | NOVEL COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ACOUSIA THERAPEUTICS GMBH (DE) | 2020-05-21 | — | — | US | claimed |
| EP-3484863-A2 | NOVEL COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | Acousia Therapeutics GmbH (DE) | 2019-05-22 | — | — | EP | claimed |
| WO-2018158256-A2 | NOVEL COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ACOUSIA THERAPEUTICS GMBH (DE) | 2018-09-07 | — | — | WO | claimed |
| EP-3366683-A1 | CYCLIC AMIDES, ACTEAMIDES AND UREAS USEFUL AS POTASSIUM CHANNEL OPENERS | Acousia Therapeutics GmbH (DE) | 2018-08-29 | — | — | EP | claimed |
| EP-4247332-B1 | NON-AQUEOUS GEL COMPOSITION | ACOUSIA THERAPEUTICS GMBH (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4725937-A1 | PROCESS FOR THE SYNTHESIS OF BICYCLIC CARBOXAMIDE COMPOUNDS | Acousia Therapeutics GmbH (DE) | 2026-04-15 | — | — | EP | disclosed |
| EP-4362916-A1 | AQUEOUS GEL COMPOSITION | Acousia Therapeutics GmbH (DE) | 2024-05-08 | — | — | EP | disclosed |
| EP-3567034-A1 | PENTACYCLOTHIENYL AND INDANYL UREA DERIVATIVES AS POTASSIUM CHANNEL OPENERS | Acousia Therapeutics GmbH (DE) | 2019-11-13 | — | — | EP | disclosed |
| EP-3484863-A2 | NOVEL COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | Acousia Therapeutics GmbH (DE) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018158256-A2 | NOVEL COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ACOUSIA THERAPEUTICS GMBH (DE) | 2018-09-07 | — | — | WO | disclosed |
| EP-3366683-A1 | CYCLIC AMIDES, ACTEAMIDES AND UREAS USEFUL AS POTASSIUM CHANNEL OPENERS | Acousia Therapeutics GmbH (DE) | 2018-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157072-A1 | NOVEL COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | KCNA7, KCNA4, KCNJ2 | HPGD 4108/4885P2RX7 165/4885KMT2A 1589/4885 |
| US-20240009149-A1 | NON-AQUEOUS GEL COMPOSITION | LIPA, MGLL, TAS2R42 | HPGD 3737/4885P2RX7 1353/4885KMT2A 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.